Toggle light / dark theme

Jellyfish are more advanced than once thought. A new study from the University of Copenhagen has demonstrated that Caribbean box jellyfish can learn at a much more complex level than ever imagined—despite only having one thousand nerve cells and no centralized brain. The finding changes our fundamental understanding of the brain and could enlighten us about our own mysterious brains.

After more than 500 million years on Earth, the immense evolutionary success of is undeniable. Still, we’ve always thought of them as simple creatures with very limited learning abilities.

The prevailing opinion is that more advanced nervous systems equate with more advanced learning potential in animals. Jellyfish and their relatives, collectively known as cnidarians, are considered to be the earliest living animals to develop nervous systems and to have fairly simple nervous systems and no centralized brain.

Discovering And Developing Medicines To Keep You Biologically Young — Dr. Marco Quarta, Ph.D. — Co-Founder and CEO, Rubedo Life Sciences; CEO, Phaedon Institute.


Dr. Marco Quarta, Ph.D. is Co-Founder and CEO of Rubedo Life Sciences (https://www.rubedolife.com/), a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The company’s proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.

Dr. Quarta received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University and continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA. While there, he established a translational program in regenerative medicine. He has over 35 publications and patents in the field of aging, stem cells, regenerative medicine, and rejuvenation.

This November, researchers, clinicians, and investors will descend on Miami, Florida for the annual Wonderland conference. This year, the world’s leading psychedelics conference is expanding its focus to include longevity for the first time, welcoming top speakers from across the field, from Bryan Johnson to Aubrey de Grey.

Through a series of keynotes, round table and panel discussions, and town hall open mic sessions, the event aims to explore the increasingly linked topics of psychedelic medicine, mental health, and longevity medicine.

Longevity. Technology: Every month it seems, more and more research is highlighting the connection between mental health and longevity – from accelerated biological aging to reduced life expectancy. With psychedelics simultaneously demonstrating compelling results in the treatment of mental conditions, from depression to PTSD, the synergies between longevity and psychedelic medicine are clear. We caught up with leading longevity physician Dr Halland Chen to tap into his views on recent developments in longevity medicine and its links with the psychedelic world.

As befits the child of a scientist, Martin Picard’s young son, 3, is already learning about biology with an age-appropriate textbook, “Cell Biology for Babies.” Picard winces a little whenever the book calls mitochondria the “powerhouses of the cell” but figures he has plenty of time as his son grows older to explain why the tiny organelles are much more than simple energy sources.

Picard is a leading proponent of mitochondrial psychobiology (a phrase he coined), an emerging field that examines how psychological states like stress influence mitochondrial functions, which in turn influence mental and physical health.

“The powerhouse analogy is outdated and one-dimensional and can impede science by limiting researchers’ perceptions of what mitochondria can do,” says Picard, associate professor of behavioral medicine in psychiatry and neurology.

Children whose mothers had a higher exposure to certain phthalates during pregnancy tend to show smaller total gray matter in their brains at age 10. This is one of the main conclusions of a study led by the NYU Grossman School of Medicine and the Barcelona Institute for Global Health (ISGlobal), and published in Molecular Psychiatry.

The study also found that to plasticizers during pregnancy is associated with lower child IQ at age 14, which confirmed the results of two previous study on the topic. Moreover, the research team observed that this relationship between exposure to certain phthalates and lower child IQ is partially influenced by total gray matter volumes. In other words: exposure to plasticizers before birth could lead to smaller total gray matter in childhood, which in turn could be related to a lower IQ.

Finally, the results showed an association between gestational exposure to plasticizers and smaller white matter volumes in girls.

Traumatic brain injury (TBI) is a leading cause of long-term disability and premature death, especially among military personnel and those playing contact sports. Substantial research has examined acute and chronic neurological consequences of TBI; however, non-neurological conditions associated with TBI are understudied.

A new review paper by investigators from Mass General Brigham presents key findings on long-term associations between TBI and cardiovascular disease, highlighting that nervous system dysfunction, neuroinflammation, changes in the brain-gut connection, and post-injury comorbidities may elevate risk of both cardiovascular and cognitive dysfunction in TBI survivors compared to the .

The review, published in The Lancet Neurology, emphasizes the need for future cardiovascular research, surveillance and intervention in TBI survivors.

Psychoses like schizophrenia cost billions of dollars annually and derail the lives of people struggling with the disease. Now Monash University researchers have modeled how the effects of psychosis spread through the brain, allowing them to isolate areas where these changes may originate from and which could be targeted by therapies designed to reduce the disease’s progression.